Document:

exv10w1

Exhibit
10.1

AMENDED AND RESTATED

EXECUTIVE EMPLOYMENT AGREEMENT

FOR JAMES P. PANEK

     This Amended and Restated Executive Employment Agreement (the “Agreement”)
is entered into by and between James P. Panek (hereinafter “Executive”) and VaxGen, Inc.
(hereinafter “VaxGen” or the “Company”), effective as of February 1, 2009 (the “Effective Date”).
This Agreement supersedes in its entirety all prior employment agreements between Executive and
VaxGen, whether signed or unsigned, including the Amendment Number One To Amended And Restated
Executive Employment Agreement Dated March 26, 2008 (the “Prior Agreement”). In consideration of
the mutual promises made herein, VaxGen and Executive agree as follows:

     1. Employment By The Company; Board Position. VaxGen hereby agrees to continue to
employ Executive in the position of President, and Executive hereby accepts continued employment
with VaxGen in the position of President, upon the terms and conditions set forth in this
Agreement. As of the Effective Date, Executive will no longer be employed in the position of Chief
Executive Officer. This Agreement will not effect Executive’s position as a Director on the
Company’s Board of Directors (the “Board”).

     2. Work Responsibilities and Work Schedule. 

          (a) Title and Responsibilities. Executive shall continue to perform the functions and
responsibilities of President as may be provided for that position in the Company’s by-laws and
articles of incorporation, customarily associated with that position, and as may be assigned from
time to time by the Board. Executive will continue to report to the Board. Executive’s primary
office location will be the Company’s corporate headquarters.

          (b) Work Schedule. As of the Effective Date, Executive’s new work schedule shall be 62.5% of
full-time (a regular work schedule of at least 25 hours a week). The parties acknowledge that this
reduction does not result in a “separation from service” under Treasury Regulation Section
1.409A-1(h). The parties anticipate that Executive will be able to perform the duties of President
within the above specified time commitments. However, Executive understands that because his
position is classified as exempt, on occasion he may be required to work additional hours as
required by his job duties and Executive will not be eligible for additional compensation or
overtime.

          (c) Discretion to Modify. Executive’s position, title, job description, reporting
relationship, office location, work schedule, duties and responsibilities may be modified from time
to time in the sole discretion of VaxGen.

     3. Compensation And Benefits.

          (a) Base Salary. Effective as of the Effective Date, VaxGen will pay Executive a base salary
at the annualized rate of one hundred ninety-five thousand dollars ($195,000), less standard
payroll deductions and withholdings and payable in accordance with

1.

 

the Company’s regular payroll schedule. Such compensation is subject to review and potential
change annually in the Board’s discretion.

          (b) One-Time Cash Payment. The Company will pay Executive a one-time cash payment of
$193,050, less standard payroll deductions and withholdings (the “Cash Payment”). This Cash
Payment is in consideration for Executive’s agreement to renegotiate his rights under the Prior
Agreement to severance benefits (which Prior Agreement benefits are exempt from the application of
Section 409A of the Code) in order to reduce the Prior Agreement cash severance payment as
reflected in Section 10(b) of this Agreement. As a condition to Executive’s receipt of the Cash
Payment, Executive must first sign, date, return to the Company, and not revoke, the Cash Payment
Release attached hereto as Exhibit A on or before February 28, 2009. The Cash Payment will be paid
within ten (10) business days after the Effective Date of the Cash Payment Release (as defined
therein).

          (c) Stock Option Grant. This Agreement does not alter or affect any stock option grants
provided to Executive by the Company as of the Effective Date, except as specifically provided in
Section 10(b)(iii) hereof. Executive acknowledges that there are no commitments on behalf of the
Company to grant to Executive any additional stock options. The Board will consider, on an annual
basis and at the Board’s sole discretion, whether to grant additional stock options to Executive.

          (d) Benefits. Executive shall be entitled to participate in the Company’s employee benefit
plans which may be in effect from time to time and provided by the Company to its senior officers
generally, including paid holidays, leaves of absence, health insurance, dental insurance, life
insurance, and other benefits, if any, in accordance with and subject to the eligibility
requirements of such employee benefit plans and other applicable policies and procedures.
Executive’s rights under such employee benefit plans, or the rights of Executive’s dependents,
shall be governed solely by the terms of such plans and any applicable policies and procedures. As
of the Effective Date, Executive shall accrue Paid Time Off (“PTO”) at a rate equal to 62.5% of the
full-time rate that otherwise would apply if he was working a full-time schedule. The Company’s
employee benefit plans, and policies and procedures related thereto, are subject to termination,
modification or limitation at any time at the Company’s sole discretion.

          (e) Business Expenses. VaxGen shall reimburse Executive for all reasonable business expenses,
including expenses incurred for travel on VaxGen business, in accordance with the policies and
procedures of VaxGen, as may be adopted or amended from time to time at VaxGen’s sole discretion.
To be eligible for reimbursement, Executive must submit business expense reimbursement requests to
VaxGen on a monthly basis, which includes supporting documentation (including receipts) reasonably
satisfactory to VaxGen.

          (f) Total Compensation. Executive agrees that the compensation stated above constitutes the
full and exclusive monetary consideration and compensation for all services provided by Executive
to the Company, and for all promises and obligations under this Agreement.

2.

 

     4. VaxGen Employment Policies.  Executive’s employment relationship will be governed
by the general employment policies and practices of the Company, and Executive agrees to abide by
all such written policies, practices and procedures, as they may from time to time be adopted or
modified by VaxGen at its sole discretion. Executive also agrees to review and abide by the
policies in VaxGen’s Employee Handbook (as they may be modified by the Company from time to time)
and to acknowledge in writing that Executive has read and will abide by the Employee Handbook.

     5. Protection of Company Information. As a condition of his continued employment,
Executive agrees to sign, contemporaneously with this Agreement, and to abide by the Employee’s
Proprietary Information and Inventions Agreement (the “Proprietary Information Agreement”), a copy
of which is attached hereto as Exhibit B. The Proprietary Information Agreement shall be deemed
effective as of the commencement of Executive’s employment with the Company.

     6. Indemnity Agreement. This Agreement does not alter or affect the Indemnity
Agreement previously entered into between Executive and the Company, a copy of which is attached
hereto as Exhibit C.

     7. Outside Activities.

          (a) Non-Company Activities. Except for any outside activities consented to in writing by the
Board, which consent will not be unreasonably withheld, Executive will not during the term of this
Agreement undertake or engage in any other employment, occupation or business enterprise, other
than ones in which Executive is a passive investor. Executive may engage in civic and
not-for-profit activities so long as such activities do not materially interfere with the
performance of Executive’s duties hereunder.

          (b) No Adverse Interests. During Executive’s employment, Executive agrees not to acquire,
assume or participate in, directly or indirectly, any position, investment or interest known by
Executive to be adverse or antagonistic to the Company’s interests, business or prospects,
financial or otherwise, except as permitted by Section 7(c).

          (c) Noncompetition. During the term of Executive’s employment by the Company, except on
behalf of the Company, Executive will not directly or indirectly, whether as an officer, director,
stockholder, partner, proprietor, associate, representative, consultant, employee, or in any
capacity whatsoever, engage in, become financially interested in, be employed by or have any
business connection with any person, corporation, firm, partnership or other entity whatsoever
which competes directly with the Company, anywhere throughout the world, in any line of business
engaged in (or planned to be engaged in) by the Company; provided, however, that Executive may own,
as a passive investor, securities of any competing public corporation, so long as Executive’s
direct holdings in any one such corporation shall not in the aggregate constitute more than one
percent (1%) of the voting stock of such corporation and any ownership interest in a competitor is
disclosed in writing to the Board.

     8. Former Employment and Third Party Agreements. Executive represents and warrants
that Executive’s past and continued employment by the Company has not

3.

 

conflicted and will not conflict with and will not be constrained by any prior employment or
consulting agreement, noncompetition agreement, proprietary information agreement or other
relationship with any third party. Executive further represents and warrants that Executive does
not possess or control confidential information arising out of prior employment, consulting, or
other third party relationships, which Executive will utilize in connection with Executive’s
employment by the Company, except as expressly authorized by that third party. Executive further
warrants that by entering into this Agreement with VaxGen, Executive is not violating any of the
terms, agreements or covenants of any agreement with any third party, including but not limited to
any previous employer, and that Executive is not under any contractual obligation that would
restrict Executive’s activities on behalf of the Company.

     9. Noninterference.

          While employed by the Company and for a period of one (1) year immediately following the
termination of Executive’s employment, Executive agrees that Executive will not, without the
express consent of the Board, or in the course and scope of performing Executive’s duties for the
Company, interfere with the business of the Company by, either directly or indirectly:

          (a) soliciting, recruiting, inducing, encouraging, or otherwise causing any employee of VaxGen
to terminate his or her employment in order to become an employee, consultant or independent
contractor to or for any other person or entity, or attempting to do so;

          (b) disclosing to any person or entity the names or addresses of, or any information
pertaining to, any current or former employees of VaxGen, to the extent such names, addresses or
other information are confidential or private; or

          (c) using Proprietary Information (as defined in the Proprietary Information Agreement) to
call on, solicit or take away any clients or customers of VaxGen or any other persons, entities, or
corporations with which VaxGen has had or contemplated any business transaction or relationship
during Executive’s employment with VaxGen (such Proprietary Information to include, but not be
limited to, investments, licenses, joint ventures, and agreements for development), or attempting
to do so.

     10. Termination Of Employment.

          (a) At-Will Employment Relationship. Executive’s employment relationship is at-will. This
means that Executive’s employment and/or this Agreement may be terminated with or without Cause (as
defined in Section 10(d)(ii)), and with or without advance notice, at any time by either Executive
or by VaxGen. Nothing in this document shall limit the right to terminate employment at will or to
terminate this Agreement at any time. This at-will employment relationship can only be changed in
a written agreement approved by the Board and signed by Executive and the Chairman of the Board.

          (b) Severance Benefits Eligibility. In the event that Executive’s employment is terminated
without Cause by the Company, or if Executive resigns for Good Reason pursuant to Section 10(c)
hereof and such termination or resignation, as the case may be, is not due either to Executive’s
death or disability and further constitutes a “separation from service” under

4.

 

Treasury Regulations Section 1.409A-1(h), Executive shall be eligible to receive the following
as Executive’s sole severance benefits (collectively, the “Severance Benefits”): (i) a lump sum
payment of $193,050, less standard withholdings and deductions, and payable, subject to the
provisions of this Section 10, within ten (10) business days after the later of (x) the effective
date of such separation from service, or (y) the date on which the Separation Date Release (as
defined below) becomes effective (the “Severance Payment”) (such later date, the “Payment Date”);
(ii) health insurance continuation coverage (pursuant to the federal COBRA law or applicable state
law) at Executive’s own expense; (iii) all stock option grants or other equity awards then held by
Executive shall be subject to accelerated vesting such that all unvested shares will become fully
vested and exercisable effective as of the date of the separation from service (the “Accelerated
Vesting”); and (iv) payment of all accrued salary and all accrued and unused vacation, as well as
accrued benefits under any written ERISA-qualified benefit plan (e.g., 401(k) plan), or written
insurance policy, to which Executive has a vested right as of the termination date. As a condition
of and prior to the receipt of all or any of the Severance Payment or Accelerated Vesting,
Executive shall provide the Company with an effective general release of all known and unknown
claims in the form attached hereto as Exhibit D (the “Separation Date Release”) not later than 60
days after the termination date.

          (c) Good Reason Resignation. Executive may resign for Good Reason due to the occurrence of
any of the following without Executive’s consent: (i) material breach by the Company of any of the
terms and provisions of this Agreement resulting in material harm to Executive; (ii) a material
reduction of Executive’s authority, duties or responsibilities; (iii) relocation of Executive’s
place of work that would increase Executive’s one-way commuting distance by more than fifty (50)
miles over Executive’s commute immediately prior thereto; or (iv) a material reduction by VaxGen of
Executive’s then-current base salary (except where such reduction is imposed uniformly on other
senior executives of the Company). Notwithstanding the foregoing, a resignation of employment by
Executive shall not constitute a resignation for Good Reason based on the conduct described above
unless (A) within thirty (30) days following the occurrence of such conduct, Executive provides
VaxGen’s Chief Executive Officer (or the Board in the case Executive is then serving as the Chief
Executive Officer or there is no one serving as the Chief Executive Officer) with written notice
specifying (x) the particulars of such conduct and (y) that Executive deems such conduct to be
described in (i), (ii), (iii) or (iv) of this Section 10(c), (B) such conduct has not been cured
within thirty (30) days following receipt by VaxGen’s Chief Executive Officer (or the Board in the
case of Executive is then serving as the Chief Executive Officer or there is no one serving as the
Chief Executive Officer) of such notice and (C) the resignation occurs within one hundred and
twenty (120) days of the occurrence of such conduct. Executive’s resignation shall be effective on
the date specified in the notice given hereunder, which date shall not be earlier than the earliest
date permitted by the preceding sentence, nor later than the latest date permitted by the preceding
sentence (unless such earlier or later resignation date is permitted by the Company).

          (d) Termination for Cause.

               (i) No Severance. In the event Executive’s employment is terminated at any time for Cause,
Executive will be entitled to payment of all accrued salary and accrued and unused vacation, but
Executive will not be entitled to the Severance Benefits, pay in lieu of notice, or any other such
compensation unless required by law.

5.

 

               (ii) Cause Definition. For the purposes of this Agreement, “Cause” for termination shall mean
any of the following: (A) fraud or conviction (including a no contest or guilty plea) of illegal
criminal acts committed by Executive; (B) Executive’s material breach of any material provision of
any written agreement with the Company, including but not limited to this Agreement or the
Proprietary Information Agreement; (C) Executive’s material failure to perform Executive’s job
duties as determined by the Board in its reasonable judgment, and after notice of such failure has
been given to Executive by the Board and Executive has had a fifteen (15) business-day period
within which to cure such failure; or (D) a material violation of any material VaxGen employment
policy, including but not limited to the policies set forth in VaxGen’s Employee Handbook.

          (e) Voluntary or Mutual Termination. In the event Executive terminates Executive’s employment
other than for Good Reason, or in the event that Executive’s employment terminates at the parties’
mutual agreement, Executive will be entitled to payment of all accrued salary and accrued and
unused vacation, but Executive will not be entitled to Severance Benefits, pay in lieu of notice,
or any other such compensation unless required by law.

          (f) Termination Due to Death or Disability. In the event of Executive’s death, Executive’s
employment will terminate on the date thereof, and Executive and Executive’s heirs or estate will
be entitled to payment of all accrued salary and accrued and unused vacation, but Executive will
not be entitled to Severance Benefits, pay in lieu of notice or any other such compensation unless
required by law. In addition, if Executive’s employment terminates due to his disability,
Executive will be entitled to payment of all accrued salary and accrued and unused vacation, but
Executive will not be entitled to Severance Benefits, pay in lieu of notice or any other such
compensation unless required by law.

          (g) Excise Tax.

               (i) Anything in this Agreement to the contrary notwithstanding, if any payment or benefit that
Executive would receive pursuant to this Agreement or otherwise from the Company (“Payment”) would
(i) constitute a “parachute payment” within the meaning of Section 280G of the Internal Revenue
Code of 1986, as amended (the “Code”), and (ii) but for this sentence, be subject to the excise
tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be equal to the
Reduced Amount (defined below). The “Reduced Amount” shall be either (i) the largest portion of
the Payment that would result in no portion of the Payment being subject to the Excise Tax, or
(ii) the full Payment, whichever amount after taking into account all applicable federal, state and
local employment taxes, income taxes, and the Excise Tax, results in Executive’s receipt, on an
after-tax basis, of the greatest amount of the Payment to Executive. If a reduction in payments or
benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced
Amount, reduction shall occur in the following order: reduction of cash payments; cancellation of
accelerated vesting of option grants; cancellation of accelerated vesting of other equity awards;
and reduction of employee benefits. In the event that acceleration of vesting of equity awards is
to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of
grant.

               (ii) The accounting firm engaged by the Company for general audit purposes as of the day prior
to the date on which the event that triggers the Payment occurs (the

6.

 

“Payment Event”) shall perform the foregoing calculations. If the accounting firm so engaged
by the Company is serving as accountant or auditor for the individual, entity or group effecting
the Payment Event, the Board shall have the discretion to appoint a nationally recognized
accounting firm to make the determinations required hereunder. The Company shall bear all expenses
with respect to the determinations by such accounting firm required to be made hereunder.

               (iii) The accounting firm engaged to make the determinations hereunder shall provide its
calculations, together with detailed supporting documentation, to the Company and Executive within
fifteen (15) calendar days after the date on which Executive’s right to a Payment is triggered (if
requested at that time by the Company or Executive) or such other time as reasonably requested by
the Company or Executive. If the accounting firm determines that no Excise Tax is payable with
respect to a Payment, either before or after the application of the Reduced Amount, it shall
furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise
Tax will be imposed with respect to such Payment. The Company shall be entitled to rely upon the
accounting firm’s determinations, which shall be final and binding.

          (h) Deferred Compensation. It is intended that all of the payments and benefits provided
under this Agreement satisfy, to the greatest extent possible, the exemptions from the application
of Section 409A of the Code provided under of Treasury Regulation Sections 1.409A-1(b)(4),
1.409A-1(b)(5) and 1.409A-1(b)(9), and that this Agreement will be construed to the greatest extent
possible as consistent with those provisions. If the Company (or, if applicable, the successor
entity thereto) determines that any of the severance payments or benefits provided to Executive
under this Agreement or otherwise (the “Severance Payments”) constitute “deferred compensation”
under Code Section 409A and Executive is a “specified employee” (as such term is defined in Section
409A(a)(2)(B)(i)) of the Company or any successor entity thereto upon his separation from service,
then, solely to the extent necessary to avoid the incurrence of the adverse personal tax
consequences under Section 409A as a result of the payment of compensation upon his “separation
from service”, the timing of the Severance Payments shall be delayed as follows: on the earlier to
occur of (i) the date that is six months and one day after the date of the separation from service
or (ii) the date of Executive’s death (such earlier date, the “Delayed Initial Payment Date”), the
Company (or the successor entity thereto, as applicable) shall (A) pay to Executive a lump sum
amount equal to the sum of the Severance Payments that Executive would otherwise have received
through the Delayed Initial Payment Date if the commencement of the payment of the Severance
Payments had not been delayed pursuant to this paragraph and (B) commence paying the balance of the
Severance Payments in accordance with the applicable payment schedules set forth above. All
payments hereunder are intended to constitute separate payments for purposes of Treasury
Regulations Section 1.409A-2(b)(2).

          (i) Board Membership. In the event Executive’s employment with VaxGen is terminated for any
reason, whether at the Company’s or Executive’s request, and Executive then is a member of the
Board, Executive agrees, unless otherwise requested by the Board, to resign Executive’s membership
on the Board effective as of the date of the termination of Executive’s employment.

7.

 

     11. General Provisions.

          (a) Governing Law. This Agreement shall be construed in accordance with and governed by the
laws of the State of California without regard to conflict of laws principles that would otherwise
apply the law of another jurisdiction. Any ambiguity in this Agreement shall not be construed
against either party as the drafter.

          (b) Complete Agreement. This Agreement, including its exhibits, constitutes the complete,
final and exclusive embodiment of the entire agreement and understanding of the parties with regard
to the subject matter hereof. It is entered into without reliance on any promise, warranty or
representation other than those expressly contained herein, and it supersedes and replaces any and
all prior or contemporaneous agreements, promises or representations between VaxGen and Executive,
whether oral, written or implied, including but not limited to all previous employment agreements
between the parties, whether signed or unsigned, and any amendments thereof. The terms of this
Agreement and any changes in Executive’s employment terms (other than those employment terms
expressly reserved to the Company’s or Board’s discretion in this Agreement), require a written
amendment to the Agreement which is approved by the Board and signed by Executive and a duly
authorized officer of the Company pursuant to authority expressly granted by the Board.

          (c) Waiver. Any waiver of a breach of this Agreement shall be in writing and shall not be
deemed to be a waiver of any successive breach.

          (d) Severability. Whenever possible, each provision of this Agreement will be interpreted in
such manner as to be effective and valid under applicable law, but if any provision of this
Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law
or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any
other provision or any other jurisdiction, and such invalid, illegal or unenforceable provision
will be reformed, construed and enforced in such jurisdiction so as to render it valid, legal, and
enforceable consistent with the general intent of the parties insofar as possible.

          (e) Voluntary Agreement. Executive and VaxGen represent and warrant that each has reviewed
all aspects of this Agreement, has carefully read and fully understands all provisions of this
Agreement, and is voluntarily entering into this Agreement. Each party represents and agrees that
such party has had the opportunity to review any and all aspects of this Agreement with the legal
and tax advisors of such party’s choice before executing this Agreement, and each party has had a
full opportunity to negotiate the terms of this Agreement prior to signing this Agreement.

          (f) Headings. The headings and captions of the various paragraphs of this Agreement are
placed herein for the convenience of the parties and the reader, do not constitute a substantive
term or terms of this Agreement, and shall not be considered in the interpretation or application
of this Agreement.

          (g) Counterparts. This Agreement may be executed in separate counterparts, any one of which
need not contain signatures of more than one party, but all of which taken

8.

 

together will constitute one and the same Agreement. Signatures transmitted via facsimile or
PDF shall be deemed the equivalent of originals.

          (h) Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of
and shall be enforceable by and against Executive and the Company, and their respective successors,
assigns, heirs, executors and administrators; except that it is agreed that Executive may not
assign any of Executive’s duties hereunder; and Executive may not assign any of Executive’s rights
hereunder without the written consent of the Company, which shall not be unreasonably withheld.

          (i) Notices. Any notices provided hereunder must be in writing and shall be deemed effective
upon, as applicable, the date of personal delivery (including personal delivery by facsimile
transmission), the date of delivery by express delivery service (e.g. Federal Express), or the
third day after mailing by certified or registered mail, return receipt requested, to the attention
of the Chairman of the Board sent to the Company’s corporate headquarters, and to Executive at
Executive’s address as listed on the Company’s payroll, or as otherwise provided in writing by
Executive to the Board.

          (j) Alternative Dispute Resolution. To ensure rapid and economical resolution of any disputes
which may arise concerning the relationship between Executive and the Company, the parties hereby
agree that any and all claims, disputes or controversies of any nature whatsoever arising out of,
or relating to, this Agreement and its enforcement, application, interpretation, performance, or
execution, Executive’s employment with the Company, or the termination of such employment, shall be
resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration in
San Francisco, California conducted before a single arbitrator by JAMS, Inc. (“JAMS”) or its
successor, under the then applicable JAMS arbitration rules. The parties each acknowledge that by
agreeing to this arbitration procedure, they waive the right to resolve any such dispute, claim or
demand through a trial by jury or judge or by administrative proceeding. Executive will have the
right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall:
(i) have the authority to compel adequate discovery for the resolution of the dispute and to award
such relief as would otherwise be available under applicable law in a court proceeding; and
(ii) issue a written statement signed by the arbitrator regarding the disposition of each claim and
the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s
essential findings and conclusions on which the award is based. The Company shall bear all JAMS’
arbitration fees and administrative costs. Nothing in this Agreement is intended to prevent either
Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm
pending the conclusion of any arbitration.

          (k) Right To Work. As required by law, this Agreement is subject to satisfactory proof of
Executive’s right to work in the United States.

9.

 

          In Witness Whereof, the parties have executed this Agreement on the dates specified
below.

	 	 	 	 	 	 	 
	 

	 	VaxGen, Inc.	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	By: /s/ Lori
Rafield 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Printed Name
	 	Lori Rafield	 	 
	 
	 	 	 	 	 	 
	 

	 	Title: Member of the
Board of
Directors 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Date:  1/29/09
	 	 

	 	 	 
	Accepted and agreed:
	 	 
	 
	 	 
	/s/ James P. Panek
 

James P. Panek

	 	 
	 
	 	 
	28 January 2009
 

Date

	 	 

Exhibit A – Cash Payment Release

Exhibit B – Employee’s Proprietary Information and Inventions Agreement

Exhibit C – Indemnity Agreement

Exhibit D – Form of Separation Date Release

10.

 

Exhibit A

CASH PAYMENT RELEASE

     In consideration of the Cash Payment to be provided to me by VaxGen, Inc. (the “Company”), and
as required by the Amended and Restated Executive Employment Agreement between the Company and me
effective as of February 1, 2009 (the “Agreement”), I hereby give the following Cash Payment
Release (the “Cash Payment Release”).

     I hereby generally and completely release the Company and its directors, officers, employees,
shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary
entities, insurers, affiliates, and assigns (collectively, the “Released Parties”) from any and all
claims, liabilities and obligations, both known and unknown, that arise out of or are in any way
related to events, acts, conduct, or omissions occurring at any time prior to or contemporaneous
with my signing of this Cash Payment Release. This general release includes, but is not limited
to: (1) all claims arising out of or in any way related to my employment with the Company; (2) all
claims related to my compensation or benefits from the Company, including salary, bonuses,
commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock
options, or any other ownership or equity interests in the Company; (3) all claims for breach of
contract and breach of the implied covenant of good faith and fair dealing, including, but not
limited to, claims based on or arising from the Agreement; (4) all tort claims, including claims
for fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all
federal, state, and local statutory claims, including claims for discrimination, harassment,
retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964
(as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination
in Employment Act (as amended) (“ADEA”), the federal Family and Medical Leave Act (“FMLA”), the
California Family Rights Act (“CFRA”), and the California Fair Employment and Housing Act (as
amended).

     Notwithstanding the foregoing, I am not releasing the Company from the following (the
“Excluded Claims”): (1) any obligation it may otherwise have to indemnify me for my acts within
the course and scope of my employment with the Company, pursuant to the articles and bylaws of the
Company, the Indemnity Agreement, or applicable law; (2) any obligations under the Agreement or
otherwise that arise after I sign the Cash Payment Release; or (3) any rights which are not
waivable as a matter of law. In addition, nothing in this Cash Payment Release prevents me from
filing, cooperating with, or participating in any proceeding before the Equal Employment
Opportunity Commission, the Department of Labor, the California Department of Fair Employment and
Housing, or another government agency, except that I hereby waive my right to any monetary benefits
in connection with any such claim, charge or proceeding. I hereby represent and warrant that,
other than the Excluded Claims, I am not aware of any claims I have or might have against any of
the Released Parties that are not included in this Cash Payment Release.

     I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have
under the ADEA, and that the consideration given for the waiver and release in the preceding
paragraph is in addition to anything of value to which I am already entitled. I further
acknowledge that I have been advised by this writing that: (1) my waiver and release do not

 

 

apply to any rights or claims that may arise after the date I sign this Cash Payment Release;
(2) I should consult with an attorney prior to signing this Cash Payment Release (although I may
choose voluntarily not to do so); (3) I have twenty-one (21) days to consider this Cash Payment
Release (although I may choose voluntarily to sign it earlier); (4) I have seven (7) days following
the date I sign this Cash Payment Release to revoke it by providing written notice of revocation to
the Chairman of the Company’s Board of Directors; and (5) this Cash Payment Release will not be
effective until the date upon which the revocation period has expired, which will be the eighth
calendar day after the date I sign it (the “Effective Date”).

     I UNDERSTAND THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS. I
acknowledge that I have read and understand Section 1542 of the California Civil Code which reads
as follows: “A general release does not extend to claims which the creditor does not know or
suspect to exist in his or her favor at the time of executing the release, which if known by him or
her must have materially affected his or her settlement with the debtor.” I hereby expressly waive
and relinquish all rights and benefits under that section and any law or legal principle of similar
effect in any jurisdiction with respect to my release of claims herein, including but not limited
to the release of unknown and unsuspected claims.

     I hereby represent that, except for the current pay period and accrued but unused paid time
off, I have no unpaid wages due or owed me by the Company, and that I have no dispute regarding
wages due or owed to me by the Company.

	 	 	 	 	 	 	 
	 

	 	By:
	 	/s/ James P. Panek
 

James P. Panek
	 	 
	 
	 	 	 	 	 	 
	 	 	Date: 29 January 2009	 	 

 

 

Exhibit B

EMPLOYEE’S PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT

EMPLOYEE’S PROPRIETARY INFORMATION

AND INVENTIONS AGREEMENT

I acknowledge that during the past period of my employment with VaxGen, Inc., a Delaware
corporation, together with its subsidiaries, affiliates, successors or assigns (hereinafter
collectively called the “Company”), and during my current and future employment with the
Company, I had, and will continue to have, access to and obtained, and will continue to obtain and
develop, proprietary information and trade secrets of the Company. In consideration of my past,
current and future employment with the Company and the compensation I have received, and will
receive, in connection therewith, and as previously agreed by me, I hereby enter into this
Employee’s Proprietary Information and Inventions Agreement (“Agreement”), which I agree is
effective retroactive to my first day of employment with the Company. I hereby agree that this
Agreement applies during my entire period of employment with the Company, and as set forth below:

	1.	 	Proprietary Information. The Company possesses and will continue to possess confidential
and proprietary information (“Proprietary Information”) that has been created,
discovered, developed, or otherwise become known to the Company (including, without
limitation, information created, discovered, developed, or made known by me during the period
of or arising out of my employment by the Company) and/or in which property rights have been
assigned or otherwise conveyed to the Company, which information has commercial value in the
business in which the Company is engaged. By way of illustration, but not limitation, such
Proprietary Information includes (i) trade secrets, processes, formulas, data, know-how,
inventions, improvements, discoveries, developments and designs, pre-clinical and clinical
data, results, reports, experiments, assays and related media and components, formulations and
procedures for producing assays and related components, and all derivatives and improvements
of the foregoing (collectively, “Inventions”); (ii) biological products and biological
material and information, both tangible and intangible, including, but not limited to,
vaccines, antibodies, proteins, tissue samples, cell lines, nucleic acids; (iii) marketing
plans, research plans, strategies, forecasts, financial data, budgets, licenses, computer
databases, standard operating procedures, personnel information, and (iv) other confidential
information, proprietary data or material applicable to the business of the Company or its
suppliers, customers (including customer lists), affiliates or collaborators (including but
not limited to Celltrion, Inc., a Korean company, and that certain joint venture established
among Company, Celltrion, Inc., and others).

	2.	 	Genentech’s Proprietary Information. By virtue of a License Agreement between the Company
and Genentech, Inc. (“Genentech”), a Services Agreement between the Company and
Genentech, and other agreement(s) that may be entered into between the Company and Genentech
(collectively, the “Genentech Agreements”), the Company and its employees have been
and will continue to be afforded substantial access to proprietary technology and information
of Genentech (collectively, “Genentech Proprietary Information”). By way of
illustration, but not limitation, Genentech Proprietary Information includes (i) trade
secrets, processes, formulas, data, ideas, know-how, inventions, improvements, discoveries,
developments and designs, pre-clinical and clinical data, results, reports, experiments,
assays and related media and components,

 

 

	 	 	formulations and procedures for producing assays and related components, and all derivatives
of the foregoing; (ii) biological products and biological material and information, both
tangible and intangible, including, but not limited to, vaccines, antibodies, proteins,
tissue samples, cell lines, nucleic acids; (iii) marketing plans, research plans,
strategies, forecasts, financial data, budgets, licenses, computer databases, standard
operating procedures, and (iv) other business or proprietary information or material
applicable to the business of Genentech or its affiliates, suppliers, customers (including
customer lists), or collaborators.
	 
	 	 	I acknowledge and agree that at all times during my employment with the Company and
thereafter, as between me and Genentech: (i) all Genentech Proprietary Information shall be
the sole property of Genentech and its assigns, and Genentech and its assigns shall be the
sole owner of all patents and other rights in connection therewith; (ii) I do not have and
shall not acquire any rights in any Genentech Proprietary Information; and (iii) I shall
hold in strictest confidence and will not disclose or use Genentech Proprietary Information
unless authorized to do so by an officer of the Company in writing. I understand and
acknowledge that Genentech is affording the Company and its employees substantial access to
Genentech Proprietary Information in connection with the Genentech Agreements in reliance on
the provisions set forth herein, and that breach of such provisions could result in
immediate material, irreparable harm to Genentech. As such, I acknowledge and agree that
Genentech is a third party beneficiary of this Agreement with the right to directly enforce
its rights hereunder, including without limitation, the rights granted to Company under
Paragraph 6.
	 
	3.	 	Obligations to Prior Employers or Other Parties. I represent that my performance of all the
terms of this Agreement and as an employee of the Company does not and will not breach any
agreement to keep in confidence proprietary information acquired by me in confidence or in
trust prior to my employment for the Company and I have not entered into, nor will I enter
into, any agreement (written or oral) in conflict herewith. I will not bring with me to the
Company or use in the performance of my responsibilities to the Company materials, information
or documents of any third party (including but not limited to former employers) unless I have
obtained written authorization from such party for their possession and use and have provided
Company with written copies of such authorizations concurrent to entering into this Agreement.
	 
	4.	 	No Unauthorized Use or Disclosure. I agree and acknowledge that at all times during my
employment with the Company, and thereafter: (i) all Proprietary Information shall be the sole
property of the Company and its assigns, and the Company and its assigns shall be the sole
owner of all patents and other rights in connection therewith, subject to the terms of the
Genentech Agreements; (ii) I do not have and shall not acquire any rights in any Proprietary
Information; and (ii) I shall hold in strictest confidence and will not disclose or use any
Proprietary Information unless and solely to the extent authorized to do so in writing by an
officer of the Company. I recognize that the Company has received and in the future will
receive from third parties their confidential or proprietary information subject to a duty on
the Company’s part to maintain the confidentiality of such information and to use it only for
certain limited purposes. I agree to hold all such confidential or proprietary information in
the strictest confidence and not to disclose it to any person, firm or corporation or to use
it except as necessary in carrying out my work for the Company consistent with Company’s
agreement with such third party.

 

 

	5.	 	Works for Hire. Original works of authorship made by me (alone or with others) within the
scope of my employment and which are protected by copyright are “works made for hire,”
pursuant to United States Copyright Act Section 101. I acknowledge and agree that this
Paragraph applies only to works made within the scope of my employment with the Company, not
to works made within the scope of any independent contractor relationship with the Company.
	 
	6.	 	Assignment. Subject to Paragraph 7 below, I agree that, as between me and the Company, all
Inventions and all trade secrets, patent, copyright and intellectual property rights worldwide
(“Proprietary Rights”) shall be the sole property of the Company and its assigns, and
the Company and its assigns shall be the sole owner of all patents and other rights in
connection herewith. I hereby assign to the Company all right, title, and interest I may have
or acquire in and to all Inventions and Proprietary Rights which are made or conceived or
reduced to practice by me (either alone or with others) during my employment with the Company.
I further agree as to all Inventions and Proprietary Rights that I will assist the Company
and Genentech in every proper way (but at the Company’s expense) to obtain and from time to
time enforce Proprietary Rights with respect to said Inventions in any and all countries. To
that end I will execute all necessary documents (including assignment of such Proprietary
Rights to the Company) and perform such acts as the Company or Genentech may desire in
association with such Proprietary Rights. My obligations to assist the Company and Genentech
with respect to such Proprietary Rights shall continue beyond the termination of my
employment, but the Company shall compensate me at a reasonable rate after such termination
for time actually spent by me at the Company’s or Genentech’s request on such assistance. I
also agree to assign to the United States government all my right, title, and interest in and
to any and all Inventions whenever such full title is required to be in the United States by a
contract between the Company and the United States or any of its agencies.
	 
	 	 	If the Company, for any reason, is unable to secure my signature on any document needed in
connection with the preceding paragraph, I hereby irrevocably designate and appoint the
Company and its officers as my agent and attorney in fact to act on my behalf to execute
such documents and to take all other lawfully permitted acts to accomplish the purposes of
the preceding paragraph.
	 
	7.	 	Labor Code Section 2870. I understand that the Company’s right with regard to certain things
invented or co-invented by me are subject to Sections 2870 of the California Labor Code, under
which I have no obligation to assign rights in an invention for which no equipment, supplies,
facilities or trade secret information of the Company was used and which was developed
entirely on my own time, and (a) which does not relate (1) to the business of the Company or
(2) to the Company’s actual or demonstrably anticipated research of development, or (b) which
does not result from any work performed by me for the Company.
	 
	8.	 	Keeping Company Informed. While I am employed by the Company, and for a period of six
months after the termination of my employment with the Company, I will promptly disclose to
the Company, or any persons designated by it, all Inventions made or conceived or reduced to
practice or learned by me, either alone or jointly with others. In connection with such
disclosures, I will advise the Company in writing of any Inventions that I believe are
governed by Section 2870 of the California Labor Code, and will

 

 

	 	 	provide all evidence necessary to support this belief. Furthermore, I will promptly
disclose to the Company all patent applications filed by me or on my behalf for the
twelve-month period following the termination of my employment with the Company.
	 
	9.	 	Record Keeping. During the term of my employment with Company I will maintain and provide to
the Company adequate and current original written records of all Inventions and original works
of authorship developed or made by me (solely or jointly with others) during the term of this
Agreement, which such records will be and remain the sole property of Company and its assigns,
and will be in the form of notes, sketches, drawings and other formats that may be specified
by Company. Such record keeping will be complete, current, accurate, organized and legible,
and will be performed in a manner acceptable for the collection of data for submission to, or
review by, the FDA.
	 
	10.	 	Prior Inventions. As a matter of record I attach hereto as Exhibit A a complete list
of all inventions or improvements relevant to the subject matter of my employment by the
Company which have been made, conceived or reduced to practice by me alone or jointly with
others prior to my employment by the Company which I desire to remove from the operation of
this Agreement; and I covenant that such list is complete. If no such list is attached to
this Agreement, I represent that I have no such inventions or improvements at the time of
signing this Agreement. Company will not, by virtue of such listing, obtain any right, title
or interest to the inventions listed on Exhibit A. In the event that I incorporate
any such inventions into any work developed by or on behalf of Company, Company is hereby
granted a nonexclusive, royalty-free, irrevocable, perpetual, worldwide, transferable and
sublicensable license to make, have made, modify, use and sell such inventions as part of or
in connection with such work. Nothing in Paragraph will limit Company’s right to develop
information, inventions and products within the areas and type of such inventions listed on
Exhibit A.
	 
	11.	 	No Conflicting Obligations; No Solicitation. I agree that during the period of my employment
by the Company, I will not, without the Company’s express written consent, engage in any
employment or activity other than for the Company in any business in which the Company is now
or may hereafter become engaged. I agree that, during the period of my employment and for a
period of one year following termination of my employment with Company for any reason, I will
not directly or indirectly (a) solicit or in any manner encourage employees or consultants of
Company to end their relationships with Company; or (b) other than on behalf of Company,
solicit the business of any customer, business affiliate or collaborator of Company with whom
I became acquainted during the course of my employment.
	 
	12.	 	Return of Company Property. Upon demand by the Company or in any event upon any termination
of my employment by me or by the Company, I will deliver to the Company all documents and data
of any nature (and all copies thereof) pertaining to my work with the Company, including
without limitation Proprietary Information, Genentech Proprietary Information, and Inventions,
and I will not take with me any such materials. In addition, I agree that all Company
physical property, including but not limited to, computers, disks or other storage media,
desks, work areas, and filing cabinets is and will remain the property of the Company and is
subject to inspection by the Company, with or without notice, at any time.

 

 

	13.	 	Successors and Assigns. This Agreement shall be binding upon my heirs, executors, assigns,
administrators and me and shall inure to the benefit of the Company, its successors and
assigns.
	 
	14.	 	Survival. The provisions of this Agreement shall survive the termination of my employment
and the assignment of this Agreement by the Company to any other successor or assignee.
	 
	15.	 	Employment. I acknowledge that nothing in this Agreement confers any employment right that
alters my status as an “at-will” employee and that I, or the Company, may terminate my
employment at any time, for any reason, with or without cause and with or without notice. In
the event that I leave the employment of Company, I agree that Company may contact my new
employer to notify it of my obligations under this Agreement.
	 
	16.	 	Entire Agreement; No Waiver. This Agreement, together with my employment agreement with the
Company, contains the final and exclusive agreement between Company and me with respect to the
subject matter contained herein and supersedes all prior and contemporaneous discussions or
agreements (whether oral, written, or in any other format). This Agreement may not be
modified except in a writing signed by both parties. The failure by either party at any time
to require performance or compliance by the other of any of its obligations or agreements
shall in no way affect the right to require such performance or compliance at any time
thereafter. The waiver of a breach of any provision of this Agreement shall not be taken or
held to be a waiver of any preceding or succeeding breach of such provision or as a waiver of
the provision itself. No waiver of any kind shall be effective or binding, unless it is in
writing and is signed by the party to be charged.
	 
	17.	 	Remedies. Any breach of Employee’s confidentiality obligations to Company, or any
unauthorized use or disclosure by a party of the other party’s proprietary information or
inventions (and, in the case of Company, any proprietary information or inventions of its
affiliates, customers, or collaborators) outside the scope of this Agreement will result in
immediate and irreparable harm to the other party, for which there will be no adequate remedy
at law, and therefore in such event, the other party will be entitled to injunctive relief and
specific performance in addition to all other legal relief available to it. In the event of a
dispute or claim in connection with this Agreement, the prevailing party will be entitled to
its reasonable attorneys fees and costs.
	 
	18.	 	Severability. If, for any reason, a court of competent jurisdiction finds any provision of
this Agreement invalid or unenforceable, then that provision will be enforced to the maximum
extent permissible and the other provisions of this Agreement will remain in full force and
effect.
	 
	19.	 	Governing Law. This Agreement will be governed and interpreted under the laws of the state
of California, without regard to its conflict of law rules or principles.

	 	 	 	 	 	 	 
	 

	 	BY: /s/ James P. Panek
 

       James P. Panek
	 	 
	 
	 	 	 	 	 	 
	 

	 	DATED:
	 	28 January 2009	 	 

 

 

Exhibit A

Prior Inventions

The following is a complete list of all inventions or improvements relevant to my employment with
VaxGen, Inc. (the “Company”) that have been made or conceived or first reduced to practice
by me alone or jointly with others prior to my engagement by the Company:

     None.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

I understand that by leaving this Exhibit blank or not filling it out that I am attesting that
there are no such prior inventions.

 

 

Exhibit C

INDEMNITY AGREEMENT

     This Indemnity Agreement (this “Agreement”) dated as of January 31, 2007, is made by
and between VaxGen, Inc., a Delaware corporation (the “Company”), and James P. Panek
(“Indemnitee”).

Recitals

     A. The Company desires to attract and retain the services of highly qualified individuals as
directors, officers, employees and agents.

     B. The Company’s bylaws (the “Bylaws”) require that the Company indemnify its directors, and
empowers the Company to indemnify its officers, employees and agents, as authorized by the Delaware
General Corporation Law, as amended (the “Code”), under which the Company is organized and such
Bylaws expressly provide that the indemnification provided therein is not exclusive and
contemplates that the Company may enter into separate agreements with its directors, officers and
other persons to set forth specific indemnification provisions.

     C. Indemnitee does not regard the protection currently provided by applicable law, the
Company’s governing documents and available insurance as adequate under the present circumstances,
and the Company has determined that Indemnitee and other directors, officers, employees and agents
of the Company may not be willing to serve or continue to serve in such capacities without
additional protection.

     D. The Company desires and has requested Indemnitee to serve or continue to serve as a
director, officer, employee or agent of the Company, as the case may be, and has proferred this
Agreement to Indemnitee as an additional inducement to serve in such capacity.

     E. Indemnitee is willing to serve, or to continue to serve, as a director, officer, employee
or agent of the Company, as the case may be, if Indemnitee is furnished the indemnity provided for
herein by the Company.

Agreement

     Now Therefore, in consideration of the mutual covenants and agreements set forth
herein, the parties hereto, intending to be legally bound, hereby agree as follows:

     1. Definitions.

          (a) Agent. For purposes of this Agreement, the term “agent” of the Company means any person
who: (i) is or was a director, officer, employee or other fiduciary of the Company or a subsidiary
of the Company; or (ii) is or was serving at the request or for the convenience of, or representing
the interests of, the Company or a subsidiary of the Company, as a director, officer, employee or
other fiduciary of a foreign or domestic corporation, partnership, joint venture, trust or other
enterprise.

 

 

          (b) Expenses. For purposes of this Agreement, the term “expenses” shall be broadly construed
and shall include, without limitation, all direct and indirect costs of any type or nature
whatsoever (including, without limitation, all attorneys’, witness, or other professional fees and
related disbursements, and other out-of-pocket costs of whatever nature), actually and reasonably
incurred by Indemnitee in connection with the investigation, defense or appeal of a proceeding or
establishing or enforcing a right to indemnification under this Agreement, the Code or otherwise,
and amounts paid in settlement by or on behalf of Indemnitee, but shall not include any judgments,
fines or penalties actually levied against Indemnitee for such individual’s violations of law. The
term “expenses” shall also include reasonable compensation for time spent by Indemnitee for which
he is not compensated by the Company or any subsidiary or third party (i) for any period during
which Indemnitee is not an agent, in the employment of, or providing services for compensation to,
the Company or any subsidiary; and (ii) if the rate of compensation and estimated time involved is
approved by the directors of the Company who are not parties to any action with respect to which
expenses are incurred, for Indemnitee while an agent of, employed by, or providing services for
compensation to, the Company or any subsidiary.

          (c) Proceedings. For purposes of this Agreement, the term “proceeding” shall be broadly
construed and shall include, without limitation, any threatened, pending, or completed action,
suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative
hearing or any other actual, threatened or completed proceeding, whether brought in the right of
the Company or otherwise and whether of a civil, criminal, administrative or investigative nature,
and whether formal or informal in any case, in which Indemnitee was, is or will be involved as a
party or otherwise by reason of: (i) the fact that Indemnitee is or was a director or officer of
the Company; (ii) the fact that any action taken by Indemnitee or of any action on Indemnitee’s
part while acting as director, officer, employee or agent of the Company; or (iii) the fact that
Indemnitee is or was serving at the request of the Company as a director, officer, employee or
agent of another corporation, partnership, joint venture, trust, employee benefit plan or other
enterprise, and in any such case described above, whether or not serving in any such capacity at
the time any liability or expense is incurred for which indemnification, reimbursement, or
advancement of expenses may be provided under this Agreement.

          (d) Subsidiary. For purposes of this Agreement, the term “subsidiary” means any corporation
or limited liability company of which more than 50% of the outstanding voting securities or equity
interests are owned, directly or indirectly, by the Company and one or more of its subsidiaries,
and any other corporation, limited liability company, partnership, joint venture, trust, employee
benefit plan or other enterprise of which Indemnitee is or was serving at the request of the
Company as a director, officer, employee, agent or fiduciary.

          (e) Independent Counsel. For purposes of this Agreement, the term “independent counsel” means
a law firm, or a partner (or, if applicable, member) of such a law firm, that is experienced in
matters of corporation law and neither presently is, nor in the past five (5) years has been,
retained to represent: (i) the Company or Indemnitee in any matter material to either such party,
or (ii) any other party to the proceeding giving rise to a claim for indemnification hereunder.
Notwithstanding the foregoing, the term “independent counsel” shall not include any person who,
under the applicable standards of professional conduct then

 

 

prevailing, would have a conflict of interest in representing either the Company or Indemnitee
in an action to determine Indemnitee’s rights under this Agreement.

     2. Agreement to Serve. Indemnitee will serve, or continue to serve, as a director, officer,
employee or agent of the Company or any subsidiary, as the case may be, faithfully and to the best
of his or her ability, at the will of such corporation (or under separate agreement, if such
agreement exists), in the capacity Indemnitee currently serves as an agent of such corporation, so
long as Indemnitee is duly appointed or elected and qualified in accordance with the applicable
provisions of the bylaws or other applicable charter documents of such corporation, or until such
time as Indemnitee tenders his or her resignation in writing; provided, however, that nothing
contained in this Agreement is intended as an employment agreement between Indemnitee and the
Company or any of its subsidiaries or to create any right to continued employment of Indemnitee
with the Company or any of its subsidiaries in any capacity.

     The Company acknowledges that it has entered into this Agreement and assumes the obligations
imposed on it hereby, in addition to and separate from its obligations to Indemnitee under the
Bylaws, to induce Indemnitee to serve, or continue to serve, as a director, officer, employee or
agent of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement
in serving as a director, officer, employee or agent of the Company.

     3. Indemnification.

          (a) Indemnification in Third Party Proceedings. Subject to Section 10 below, the Company
shall indemnify Indemnitee to the fullest extent permitted by the Code, as the same may be amended
from time to time (but, only to the extent that such amendment permits Indemnitee to broader
indemnification rights than the Code permitted prior to adoption of such amendment), if Indemnitee
is a party to or threatened to be made a party to or otherwise involved in any proceeding, for any
and all expenses, actually and reasonably incurred by Indemnitee in connection with the
investigation, defense, settlement or appeal of such proceeding.

          (b) Indemnification in Derivative Actions and Direct Actions by the Company. Subject to
Section 10 below, the Company shall indemnify Indemnitee to the fullest extent permitted by the
Code, as the same may be amended from time to time (but, only to the extent that such amendment
permits Indemnitee to broader indemnification rights than the Code permitted prior to adoption of
such amendment), if Indemnitee is a party to or threatened to be made a party to or otherwise
involved in any proceeding by or in the right of the Company to procure a judgment in its favor,
against any and all expenses actually and reasonably incurred by Indemnitee in connection with the
investigation, defense, settlement, or appeal of such proceedings.

     4. Indemnification of Expenses of Successful Party. Notwithstanding any other provision of
this Agreement, to the extent that Indemnitee has been successful on the merits or otherwise in
defense of any proceeding or in defense of any claim, issue or matter therein, including the
dismissal of any action without prejudice, the Company shall indemnify

 

 

Indemnitee against all expenses actually and reasonably incurred in connection with the
investigation, defense or appeal of such proceeding.

     5. Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement
to indemnification by the Company for some or a portion of any expenses actually and reasonably
incurred by Indemnitee in the investigation, defense, settlement or appeal of a proceeding, but is
precluded by applicable law or the specific terms of this Agreement to indemnification for the
total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof
to which Indemnitee is entitled.

     6. Advancement of Expenses. To the extent not prohibited by law, the Company shall advance
the expenses incurred by Indemnitee in connection with any proceeding, and such advancement shall
be made within twenty (20) days after the receipt by the Company of a statement or statements
requesting such advances (which shall include invoices received by Indemnitee in connection with
such expenses but, in the case of invoices in connection with legal services, any references to
legal work performed or to expenditures made that would cause Indemnitee to waive any privilege
accorded by applicable law shall not be included with the invoice) and upon request of the Company,
an undertaking to repay the advancement of expenses if and to the extent that it is ultimately
determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that
Indemnitee is not entitled to be indemnified by the Company. Advances shall be unsecured, interest
free and without regard to Indemnitee’s ability to repay the expenses. Advances shall include any
and all expenses actually and reasonably incurred by Indemnitee pursuing an action to enforce
Indemnitee’s right to indemnification under this Agreement, or otherwise and this right of
advancement, including expenses incurred preparing and forwarding statements to the Company to
support the advances claimed. Indemnitee acknowledges that the execution and delivery of this
Agreement shall constitute an undertaking providing that Indemnitee shall, to the fullest extent
required by law, repay the advance if and to the extent that it is ultimately determined by a court
of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not
entitled to be indemnified by the Company. The right to advances under this Section shall continue
until final disposition of any proceeding, including any appeal therein. This Section 6 shall not
apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 10(b).

     7. Notice and Other Indemnification Procedures.

          (a) Notification of Proceeding. Indemnitee will notify the Company in writing promptly upon
being served with any summons, citation, subpoena, complaint, indictment, information or other
document relating to any proceeding or matter which may be subject to indemnification or
advancement of expenses covered hereunder. The failure of Indemnitee to so notify the Company
shall not relieve the Company of any obligation which it may have to Indemnitee under this
Agreement or otherwise.

          (b) Request for Indemnification and Indemnification Payments. Indemnitee shall notify the
Company promptly in writing upon receiving notice of nay demand, judgment or other requirement for
payment that Indemnitee reasonably believes to the subject to indemnification under the terms of
this Agreement, and shall request payment thereof by the Company. Indemnification payments
requested by Indemnitee under Section 3 hereof shall be

 

 

made by the Company no later than sixty (60) days after receipt of the written request of
Indemnitee. Claims for advancement of expenses shall be made under the provisions of Section 6
herein.

          (c) Application for Enforcement. In the event the Company fails to make timely payments as
set forth in Sections 6 or 7(b) above, Indemnitee shall have the right to apply to any court of
competent jurisdiction for the purpose of enforcing Indemnitee’s right to indemnification or
advancement of expenses pursuant to this Agreement. In such an enforcement hearing or proceeding,
the burden of proof shall be on the Company to prove by that indemnification or advancement of
expenses to Indemnitee is not required under this Agreement or permitted by applicable law. Any
determination by the Company (including its Board of Directors, stockholders or independent
counsel) that Indemnitee is not entitled to indemnification hereunder, shall not be a defense by
the Company to the action nor create any presumption that Indemnitee is not entitled to
indemnification or advancement of expenses hereunder.

          (d) Indemnification of Certain Expenses. The Company shall indemnify Indemnitee against all
expenses incurred in connection with any hearing or proceeding under this Section 7 unless the
Company prevails in such hearing or proceeding on the merits in all material respects.

     8. Assumption of Defense. In the event the Company shall be requested by Indemnitee to pay
the expenses of any proceeding, the Company, if appropriate, shall be entitled to assume the
defense of such proceeding, or to participate to the extent permissible in such proceeding, with
counsel reasonably acceptable to Indemnitee. Upon assumption of the defense by the Company and the
retention of such counsel by the Company, the Company shall not be liable to Indemnitee under this
Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same
proceeding, provided that Indemnitee shall have the right to employ separate counsel in such
proceeding at Indemnitee’s sole cost and expense. Notwithstanding the foregoing, if Indemnitee’s
counsel delivers a written notice to the Company stating that such counsel has reasonably concluded
that there may be a conflict of interest between the Company and Indemnitee in the conduct of any
such defense or the Company shall not, in fact, have employed counsel or otherwise actively pursued
the defense of such proceeding within a reasonable time, then in any such event the fees and
expenses of Indemnitee’s counsel to defend such proceeding shall be subject to the indemnification
and advancement of expenses provisions of this Agreement.

     9. Insurance. To the extent that the Company maintains an insurance policy or policies
providing liability insurance for directors, officers, employees, or agents of the Company or of
any subsidiary (“D&O Insurance”), Indemnitee shall be covered by such policy or policies in
accordance with its or their terms to the maximum extent of the coverage available for any such
director, officer, employee or agent under such policy or policies. If, at the time of the receipt
of a notice of a claim pursuant to the terms hereof, the Company has D&O Insurance in effect, the
Company shall give prompt notice of the commencement of such proceeding to the insurers in
accordance with the procedures set forth in the respective policies. The Company shall thereafter
take all necessary or desirable action to

 

 

cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such
proceeding in accordance with the terms of such policies.

     10. Exceptions.

          (a) Certain Matters. Any provision herein to the contrary notwithstanding, the Company shall
not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee on account of any
proceeding with respect to (i) remuneration paid to Indemnitee if it is determined by final
judgment or other final adjudication that such remuneration was in violation of law (and, in this
respect, both the Company and Indemnitee have been advised that the Securities and Exchange
Commission believes that indemnification for liabilities arising under the federal securities laws
is against public policy and is, therefore, unenforceable and that claims for indemnification
should be submitted to appropriate courts for adjudication, as indicated in Section 10(d) below);
(ii) a final judgment rendered against Indemnitee for an accounting, disgorgement or repayment of
profits made from the purchase or sale by Indemnitee of securities of the Company against
Indemnitee pursuant to the provisions of Section 16(b) of the Securities Exchange Act of 1934, as
amended, or other provisions of any federal, state or local statute or rules and regulations
thereunder; (iii) a final judgment or other final adjudication that Indemnitee’s conduct was in bad
faith, knowingly fraudulent or deliberately dishonest or constituted willful misconduct (but only
to the extent of such specific determination); or (iv) on account of conduct that is established by
a final judgment as constituting a breach of Indemnitee’s duty of loyalty to the Company or
resulting in any personal profit or advantage to which Indemnitee is not legally entitled. For
purposes of the foregoing sentence, a final judgment or other adjudication may be reached in either
the underlying proceeding or action in connection with which indemnification is sought or a
separate proceeding or action to establish rights and liabilities under this Agreement.

          (b) Claims Initiated by Indemnitee. Any provision herein to the contrary notwithstanding, the
Company shall not be obligated to indemnify or advance expenses to Indemnitee with respect to
proceedings or claims initiated or brought by Indemnitee against the Company or its directors,
officers, employees or other agents and not by way of defense, except (i) with respect to
proceedings brought to establish or enforce a right to indemnification under this Agreement or
under any other agreement, provision in the Bylaws or Certificate of Incorporation or applicable
law, or (ii) with respect to any other proceeding initiated by Indemnitee that is either approved
by the Board of Directors or Indemnitee’s participation is required by applicable law. However,
indemnification or advancement of expenses may be provided by the Company in specific cases if the
Board of Directors determines it to be appropriate.

          (c) Unauthorized Settlements. Any provision herein to the contrary notwithstanding, the
Company shall not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee
under this Agreement for any amounts paid in settlement of a proceeding effected without the
Company’s written consent. Neither the Company nor Indemnitee shall unreasonably withhold consent
to any proposed settlement; provided, however, that the Company may in any event decline to consent
to (or to otherwise admit or agree to any liability for indemnification hereunder in respect of)
any proposed settlement if the Company is also a

 

 

party in such proceeding and determines in good faith that such settlement is not in the best
interests of the Company and its stockholders.

          (d) Securities Act Liabilities. Any provision herein to the contrary notwithstanding, the
Company shall not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee or
otherwise act in violation of any undertaking appearing in and required by the rules and
regulations promulgated under the Securities Act of 1933, as amended (the “Act”), or in any
registration statement filed with the SEC under the Act. Indemnitee acknowledges that paragraph
(h) of Item 512 of Regulation S-K currently generally requires the Company to undertake in
connection with any registration statement filed under the Act to submit the issue of the
enforceability of Indemnitee’s rights under this Agreement in connection with any liability under
the Act on public policy grounds to a court of appropriate jurisdiction and to be governed by any
final adjudication of such issue. Indemnitee specifically agrees that any such undertaking shall
supersede the provisions of this Agreement and to be bound by any such undertaking.

     11. Nonexclusivity and Survival of Rights. The provisions for indemnification and advancement
of expenses set forth in this Agreement shall not be deemed exclusive of any other rights which
Indemnitee may at any time be entitled under any provision of applicable law, the Company’s
Certificate of Incorporation, Bylaws or other agreements, both as to action in Indemnitee’s
official capacity and Indemnitee’s action as an agent of the Company, in any court in which a
proceeding is brought, and Indemnitee’s rights hereunder shall continue after Indemnitee has ceased
acting as an agent of the Company and shall inure to the benefit of the heirs, executors,
administrators and assigns of Indemnitee. The obligations and duties of the Company to Indemnitee
under this Agreement shall be binding on the Company and its successors and assigns until
terminated in accordance with its terms. The Company shall require any successor (whether direct
or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the
business or assets of the Company, expressly to assume and agree to perform this Agreement in the
same manner and to the same extent that the Company would be required to perform if no such
succession had taken place.

     No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or
restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by
such Indemnitee in his or her corporate status prior to such amendment, alteration or repeal. To
the extent that a change in the Code, whether by statute or judicial decision, permits greater
indemnification or advancement of expenses than would be afforded currently under the Company’s
Certificate of Incorporation, Bylaws and this Agreement, it is the intent of the parties hereto
that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No
right or remedy herein conferred is intended to be exclusive of any other right or remedy, and
every other right and remedy shall be cumulative and in addition to every other right and remedy
given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or
employment of any right or remedy hereunder, or otherwise, by Indemnitee shall not prevent the
concurrent assertion or employment of any other right or remedy by Indemnitee.

     12. Term. This Agreement shall continue until and terminate upon the later of: (a) five (5)
years after the date that Indemnitee shall have ceased to serve as a director or and/or

 

 

officer, employee or agent of the Company; or (b) one (1) year after the final termination of
any proceeding, including any appeal then pending, in respect to which Indemnitee was granted
rights of indemnification or advancement of expenses hereunder.

     No legal action shall be brought and no cause of action shall be asserted by or in the right
of the Company against an Indemnitee or an Indemnitee’s estate, spouse, heirs, executors or
personal or legal representatives after the expiration of five (5) years from the date of accrual
of such cause of action, and any claim or cause of action of the Company shall be extinguished and
deemed released unless asserted by the timely filing of a legal action within such five-year
period; provided, however, that if any shorter period of limitations is otherwise applicable to
such cause of action, such shorter period shall govern.

     13. Subrogation. In the event of payment under this Agreement, the Company shall be
subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who, at
the request and expense of the Company, shall execute all papers required and shall do everything
that may be reasonably necessary to secure such rights, including the execution of such documents
necessary to enable the Company effectively to bring suit to enforce such rights.

     14. Interpretation of Agreement. It is understood that the parties hereto intend this
Agreement to be interpreted and enforced so as to provide indemnification to Indemnitee to the
fullest extent now or hereafter permitted by law.

     15. Severability. If any provision of this Agreement shall be held to be invalid, illegal or
unenforceable for any reason whatsoever, (a) the validity, legality and enforceability of the
remaining provisions of the Agreement (including without limitation, all portions of any paragraphs
of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that
are not themselves invalid, illegal or unenforceable) shall not in any way be affected or impaired
thereby; and (b) to the fullest extent possible, the provisions of this Agreement (including,
without limitation, all portions of any paragraph of this Agreement containing any such provision
held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or
unenforceable) shall be construed so as to give effect to the intent manifested by the provision
held invalid, illegal or unenforceable and to give effect to Section 14 hereof.

     16. Amendment and Waiver. No supplement, modification, amendment, or cancellation of this
Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of
the provisions of this Agreement shall be deemed or shall constitute a waiver of any other
provision hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.

     17. Notice. Except as otherwise provided herein, any notice or demand which, by the
provisions hereof, is required or which may be given to or served upon the parties hereto shall be
in writing and, if by telegram, telecopy or telex, shall be deemed to have been validly served,
given or delivered when sent, if by overnight delivery, courier or personal delivery, shall be
deemed to have been validly served, given or delivered upon actual delivery and, if mailed, shall
be deemed to have been validly served, given or delivered three (3) business days after deposit in
the United States mail, as registered or certified mail, with proper postage prepaid and addressed
to the party or parties to be notified at the addresses set forth on the signature page of this

 

 

Agreement (or such other address(es) as a party may designate for itself by like notice). If
to the Company, notices and demands shall be delivered to the attention of the Secretary of the
Company.

     18. Governing Law. This Agreement shall be governed exclusively by and construed according to
the laws of the State of California, as applied to contracts between California residents entered
into and to be performed entirely within California.

     19. Counterparts. This Agreement may be executed in one or more counterparts, each of which
shall for all purposes be deemed to be an original but all of which together shall constitute but
one and the same Agreement. Only one such counterpart need be produced to evidence the existence
of this Agreement.

     20. Headings. The headings of the sections of this Agreement are inserted for convenience
only and shall not be deemed to constitute part of this Agreement or to affect the construction
hereof.

     21. Entire Agreement. This Agreement constitutes the entire agreement between the parties
with respect to the subject matter hereof and supersedes all prior agreements, understandings and
negotiations, written and oral, between the parties with respect to the subject matter of this
Agreement; provided, however, that this Agreement is a supplement to and in furtherance of the
Company’s Certificate of Incorporation, Bylaws, the Code and any other applicable law, and shall
not be deemed a substitute therefor, and does not diminish or abrogate any
rights of Indemnitee thereunder.

 

 

          In Witness Whereof, the parties hereto have entered into this Agreement effective as
of the date first above written.

	 	 	 	 	 
	 	VaxGen, Inc.

 	 
	 	By:  	/s/ Matthew J. Pfeffer
 	 
	 	 	Name:  	Matthew J. Pfeffer 	 
	 	 	Title:  	SVP, CFO & Secretary 	 
	 
	 	INDEMNITEE

 	 
	 	/s/ James P. Panek
 	 
	 	Signature of Indemnitee 	 
	 	 	 
	 	James P. Panek
 	 
	 	Print or Type Name of Indemnitee 	 
	 	 	 
	 

 

 

Exhibit D

FORM OF SEPARATION DATE RELEASE

     In consideration for the Severance Benefits and other consideration provided to me by VaxGen,
Inc. (the “Company”), and as required by the Amended and Restated Executive Employment Agreement
between the Company and me effective as of February 1, 2009 (the “Agreement”), I hereby give the
following Separation Date Release (the “Separation Date Release”).

     I hereby generally and completely release the Company and its directors, officers, employees,
shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary
entities, insurers, affiliates, and assigns (collectively, the “Released Parties”) from any and all
claims, liabilities and obligations, both known and unknown, that arise out of or are in any way
related to events, acts, conduct, or omissions occurring at any time prior to or contemporaneous
with my signing of this Separation Date Release. This general release includes, but is not limited
to: (1) all claims arising out of or in any way related to my employment with the Company or the
termination of that employment; (2) all claims related to my compensation or benefits from the
Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance
pay, fringe benefits, stock, stock options, or any other ownership or equity interests in the
Company; (3) all claims for breach of contract, wrongful termination, and breach of the implied
covenant of good faith and fair dealing, including, but not limited to, claims based on or arising
from the Agreement; (4) all tort claims, including claims for fraud, defamation, emotional
distress, and discharge in violation of public policy; and (5) all federal, state, and local
statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or
other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans
with Disabilities Act of 1990, the federal Age Discrimination in Employment Act (as amended)
(“ADEA”), the federal Family and Medical Leave Act (“FMLA”), the California Family Rights Act
(“CFRA”), and the California Fair Employment and Housing Act (as amended).

     Notwithstanding the foregoing, I am not releasing the Company from the following (the
“Excluded Claims”): (1) any obligation it may otherwise have to indemnify me for my acts within
the course and scope of my employment with the Company, pursuant to the articles and bylaws of the
Company, the Indemnity Agreement, or applicable law; or (2) any rights which are not waivable as a
matter of law. In addition, nothing in this Separation Date Release prevents me from filing,
cooperating with, or participating in any proceeding before the Equal Employment Opportunity
Commission, the Department of Labor, the California Department of Fair Employment and Housing, or
another government agency, except that I hereby waive my right to any monetary benefits in
connection with any such claim, charge or proceeding. I hereby represent and warrant that, other
than the Excluded Claims, I am not aware of any claims I have or might have against any of the
Released Parties that are not included in this Separation Date Release.

     I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have
under the ADEA, and that the consideration given for the waiver and release in the preceding
paragraph is in addition to anything of value to which I am already entitled. I further

 

 

acknowledge that I have been advised by this writing that: (1) my waiver and release do not
apply to any rights or claims that may arise after the date I sign this Separation Date Release;
(2) I should consult with an attorney prior to signing this Separation Date Release (although I may
choose voluntarily not to do so); (3) I have twenty-one (21) days to consider this Separation Date
Release (although I may choose voluntarily to sign it earlier); (4) I have seven (7) days following
the date I sign this Separation Date Release to revoke it by providing written notice of revocation
to the Chairman of the Company’s Board of Directors; and (5) this Separation Date Release will not
be effective until the date upon which the revocation period has expired, which will be the eighth
calendar day after the date I sign it (the “Effective Date”).

     I UNDERSTAND THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS. I
acknowledge that I have read and understand Section 1542 of the California Civil Code which reads
as follows: “A general release does not extend to claims which the creditor does not know or
suspect to exist in his or her favor at the time of executing the release, which if known by him or
her must have materially affected his or her settlement with the debtor.” I hereby expressly waive
and relinquish all rights and benefits under that section and any law or legal principle of similar
effect in any jurisdiction with respect to my release of claims herein, including but not limited
to the release of unknown and unsuspected claims.

     I hereby represent that I have been paid all compensation owed and for all hours worked, I
have received all the leave and leave benefits and protections for which I am eligible, pursuant to
FMLA, CFRA, or otherwise, and I have not suffered any on-the-job injury for which I have not
already filed a workers’ compensation claim.

	 	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

James P. Panek
	 	 
	 
	 	 	 	 	 	 
	 

	 	Date:exv10w5

Exhibit 10.5

PROGRESS SOFTWARE CORPORATION

2002 NONQUALIFIED STOCK PLAN

(Reflecting amendments thru October 15, 2008)

SECTION 1. General Purpose of the Plan; Definitions

     The name of the plan is the Progress Software Corporation 2002 Nonqualified Stock Plan (the
“Plan”). The purpose of the Plan is to encourage and enable employees of Progress Software
Corporation, a Massachusetts corporation (the “Company”), and its Subsidiaries to acquire a
proprietary interest in the Company. It is anticipated that providing employees with a direct
stake in the Company’s welfare will assure a closer identification of their interests with those of
the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and
strengthening their desire to remain with the Company. The Company intends that this purpose will
be effected by the granting of Awards (as defined below) under the Plan.

     The following terms shall be defined as set forth below:

     “Affiliate” means any company in an “affiliated group,” as such term is defined in Section
1504(a) of the Code, which includes the Company.

     “Award” or “Awards,” except where referring to a particular category of grant under the Plan,
shall include Non-Statutory Stock Options, Restricted Stock Awards, Unrestricted Stock Awards and
Performance Share Awards.

     “Board” means the Board of Directors of the Company.

     “Cause” means (i) any material breach by the participant of any agreement to which the
participant and the Company are both parties, (ii) any act or omission to act by the participant
which may have a material and adverse effect on the Company’s business or on the participant’s
ability to perform services for the Company, including, without limitation, the commission of any
crime (other than ordinary traffic violations), or (iii) any material misconduct or material
neglect of duties by the participant in connection with the business or affairs of the Company or
any affiliate of the Company.

     “Change of Control” shall have the meaning set forth in Section 15.

     “Code” means the Internal Revenue Code of 1986, as amended, and any successor code, and
related rules, regulations and interpretations.

     “Committee” shall mean the Board or, if appointed by the Board, a committee of not less than
two (2) directors. It is the intention of the Company that the Plan shall be administered by
“non-employee directors” within the meaning of Rule 16b-3 under the Securities Exchange Act of
1934, as amended, but the authority and validity of any act taken or not taken by the

 

 

Committee shall not be affected if any director administering the Plan is not a non-employee
director.

     “Disability” means disability as set forth in Section 22(e)(3) of the Code.

     “Effective Date” means the date on which the Plan is adopted by the Board as set forth in
Section 17.

     “Eligible Person” shall have the meaning set forth in Section 4.

     “Fair Market Value” on any given date means the closing price per share of the Stock on such
date as reported by a nationally recognized stock exchange, or, if the Stock is not listed on such
an exchange, as reported by the Nasdaq Stock Market, or, if the Stock is not quoted by the Nasdaq
Stock Market, the fair market value of the Stock as determined by the Committee.

     “Non-Statutory Stock Option” means any stock option that is not an incentive stock option as
defined in Section 422 of the Code.

     “Normal Retirement” means retirement from active employment with the Company and its
Subsidiaries in accordance with the retirement policies of the Company and its Subsidiaries then in
effect.

     “Officer” means an officer as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934,
as amended.

     “Performance Share Award” means an Award granted pursuant to Section 8.

     “Restricted Stock” shall have the meaning set forth in Section 6.

     “Restricted Stock Award” means an Award granted pursuant to Section 6.

     “Stock” means the common stock, $0.01 par value per share, of the Company, subject to
adjustments pursuant to Section 3.

     “Stock Option” means any option to purchase shares of Stock granted pursuant to Section 5.

     “Subsidiary” means a subsidiary as defined in Section 424 of the Code.

     “Unrestricted Stock Award” means an award granted pursuant to Section 7.

			
	SECTION 2.	 	Administration of Plan; Committee Authority to Select Participants and Determine Awards

     (a) Committee. The Plan shall be administered by the Committee. The Committee shall select
one of its members as its chairman and shall hold its meetings at such times and places as it shall
deem advisable. A majority of its members shall constitute a quorum, and all actions of the
Committee shall require the affirmative vote of a majority of its members. Any action may be taken
by a written instrument signed by all of the members, and any action so

- 2 -

 

taken shall be as fully effective as if it had been taken by a vote of a majority of the members at
a meeting duly called and held. Except as specifically reserved to the Board under the terms of
the Plan, the Committee shall have full and final authority to operate, manage and administer the
Plan on behalf of the Company. Action by the Committee shall require the affirmative vote of a
majority of all members thereof.

     (b) Powers of Committee. The Committee shall have the power and authority to grant and modify
Awards consistent with the terms of the Plan, including the power and authority:

     (i) to select the persons to whom Awards may from time to time be granted;

     (ii) to determine the time or times of grant, and the extent, if any, of Non-Statutory
Stock Options, Restricted Stock, Unrestricted Stock and Performance Shares, or any combination
of the foregoing, granted to any one or more participants;

     (iii) to determine the number of shares to be covered by any Award;

     (iv) to determine and modify the terms and conditions, including restrictions, not
inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ
among individual Awards and participants, and to approve the form of written instruments
evidencing the Awards; provided, however, that no such action shall adversely affect rights
under any outstanding Award without the participant’s consent;

     (v) to accelerate the exercisability or vesting of all or any portion of any Award;

     (vi) subject to the provisions of Section 5(b), to extend the period in which any
outstanding Stock Option may be exercised;

     (vii) to determine whether, to what extent, and under what circumstances Stock and other
amounts payable with respect to an Award shall be deferred either automatically or at the
election of the participant and whether and to what extent the Company shall pay or credit
amounts equal to interest (at rates determined by the Committee) or dividends or deemed
dividends on such deferrals;

     (viii) to delegate to other persons the responsibility for performing ministerial actions
in furtherance of the Plan’s purpose; and

     (ix) to adopt, alter and repeal such rules, guidelines and practices for administration
of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the
terms and provisions of the Plan and any Award (including related written instruments); to
make all determinations it deems advisable for the administration of the Plan; to decide all
disputes arising in connection with the Plan; and to otherwise supervise the administration of
the Plan.

     All decisions and interpretations of the Committee shall be binding on all persons, including
the Company and Plan participants.

- 3 -

 

SECTION 3. Shares Issuable under the Plan; Mergers; Substitution

     (a) Shares Issuable. The maximum number of shares of Stock with respect to which Awards may
be granted under the Plan, subject to adjustment upon changes in capitalization of the Company as
provided in this Section 3, shall be six million five hundred thousand (6,500,000) shares of Stock.
For purposes of this limitation, if any shares of Stock covered by an Award granted under the
Plan, or to which such an Award relates, are repurchased or forfeited, or if an Award has expired,
terminated or been canceled for any reason whatsoever (other than by reason of exercise or
vesting), then such shares of Stock or the shares of Stock covered by such Award, as the case may
be, shall be added back to the shares of Stock with respect to which Awards may be granted under
the Plan. Subject to such overall limitation, any type or types of Award may be granted with
respect to shares of Stock. Shares of Stock issued under the Plan may be authorized but unissued
shares or shares reacquired by the Company.

     (b) Stock Dividends, Mergers, etc. In the event that the Company effects a stock dividend,
stock split or similar change in capitalization affecting the Stock, the Committee shall make
appropriate adjustments in (i) the number and kind of shares of stock or securities with respect to
which Awards may thereafter be granted (including without limitation the limitations set forth in
Section 3(a) above), (ii) the number and kind of shares remaining subject to outstanding Awards,
and (iii) the option or purchase price in respect of such shares. In the event of the merger,
consolidation, dissolution or liquidation of the Company, the Committee in its sole discretion may,
as to any outstanding Awards, make such substitution or adjustment in the aggregate number of
shares reserved for issuance under the Plan and in the number and purchase price (if any) of shares
subject to such Awards as it may determine and as may be permitted by the terms of such
transaction, or accelerate, amend or terminate such Awards upon such terms and conditions as it
shall provide (which, in the case of the termination of the vested portion of any Award, shall
require payment or other consideration which the Committee deems equitable in the circumstances).

     (c) Substitute Awards. The Committee may grant Awards under the Plan by assumption of or in
substitution for stock and stock-based awards granted or issued by another company to its
directors, officers, employees, consultants and other service providers if such persons become
Eligible Persons in connection with an acquisition of that company or any division thereof by the
Company, whether by merger, consolidation, purchase of stock, purchase of assets or otherwise. The
Committee may direct that the substitute awards be granted on such terms and conditions as the
Committee considers appropriate in the circumstances. Shares which may be delivered under such
substitute awards may be in addition to the maximum number of shares provided for in Section 3(a).

SECTION 4. Eligibility

     Awards may be granted to employees of the Company or its Subsidiaries, and to consultants or
other persons who render services to the Company, regardless of whether they are also employees
(“Eligible Persons”), provided, however, that members of the Board and Officers are not eligible to
receive Awards under the Plan.

- 4 -

 

SECTION 5. Stock Options

     The Committee may grant Stock Options to Eligible Persons pursuant to the Plan. Any Stock
Option granted under the Plan shall be in writing and in such form as the Committee may from time
to time approve. Stock Options granted under the Plan shall be Non-Statutory Stock Options.

     The Committee in its discretion may determine the effective date of Stock Options. Stock
Options granted pursuant to this Section 5 shall be subject to the following terms and conditions
and the terms and conditions of Section 9 and shall contain such additional terms and conditions,
not inconsistent with the terms of the Plan, as the Committee shall deem desirable:

     (a) Exercise Price. The exercise price per share for the Stock covered by a Stock Option
granted pursuant to this Section 5 shall be determined by the Committee at the time of grant;
provided, however, that the exercise price shall not be less than Fair Market Value on the date of
grant.

     (b) Option Term. The term of each Stock Option shall be fixed by the Committee, but no Stock
Option shall be exercisable more than ten (10) years after the date the Stock Option is granted.

     (c) Exercisability; Rights of a Stockholder. Stock Options shall become vested and
exercisable at such time or times, whether or not in installments, and upon such conditions, as
shall be determined by the Committee at or after the grant date. The Committee may at any time
accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have
the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not
as to unexercised Stock Options.

     (d) Method of Exercise. Stock Options may be exercised in whole or in part, by delivering
written notice of exercise to the Company, specifying the number of shares to be purchased.
Payment of the purchase price may be made by one or more of the following methods:

     (i) in cash, by certified or bank check or other instrument acceptable to the
Committee;

     (ii) with the consent of the Committee, in the form of shares of Stock owned by the
optionee for a period of at least six (6) months and not then subject to restrictions. Such
surrendered shares shall be valued at Fair Market Value on the exercise date;

     (iii) with the consent of the Committee, by the optionee delivering to the Company a
properly executed exercise notice together with irrevocable instructions to a broker to
promptly deliver to the Company cash or a check payable and acceptable to the Company to pay
the purchase price; provided that in the event the optionee chooses to pay the purchase
price as so provided, the optionee and the broker shall comply with such procedures and
enter into such agreements of indemnity and other agreements as the Committee shall
prescribe as a condition of such payment procedure. The Company need

- 5 -

 

not act upon such exercise notice until the Company receives full payment of the exercise
price; or

     (iv) by any other means (including, without limitation, by delivery of a promissory
note of the optionee payable on such terms as are specified by the Committee; provided,
however, that the interest rate borne by such note shall not be less than the lowest
applicable federal rate, as defined in Section 1247(d) of the Code) which the Committee
determines are consistent with the purpose of the Plan and with applicable laws and
regulations.

     The delivery of certificates representing shares of Stock to be purchased pursuant to the
exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting
in his stead in accordance with the provisions of the Stock Option) by the Company of the full
purchase price for such shares and the fulfillment of any other requirements contained in the Stock
Option or imposed by applicable laws and regulations, as determined by the Committee in its sole
discretion.

     (e) Transferability of Options. No Stock Option shall be transferable by the optionee
otherwise than by will or by the laws of descent and distribution, and all Stock Options shall be
exercisable, during the optionee’s lifetime, only by the optionee or his or her legal
representative; provided, however, that the Committee may, in the manner established by the
Committee, permit the transfer, without payment of consideration, of a Non-Statutory Stock Option
by an optionee to a member of the optionee’s immediate family or to a trust or partnership whose
beneficiaries are members of the optionee’s immediate family; and such transferee shall remain
subject to all the terms and conditions applicable to the option prior to the transfer. For
purposes of this provision, an optionee’s “immediate family” shall mean the holder’s spouse,
children and grandchildren.

     (f) Form of Settlement. Shares of Stock issued upon exercise of a Stock Option shall be free
of all restrictions under the Plan, except as otherwise provided in this Plan or in the terms of
such Stock Option.

SECTION 6. Restricted Stock Awards

     (a) Nature of Restricted Stock Award. The Committee in its discretion may grant Restricted
Stock Awards to any Eligible Person, entitling the recipient to acquire, for a purchase price
determined by the Committee (but not less than Fair Market Value on the date of grant), shares of
Stock subject to such restrictions and conditions as the Committee may determine at the time of
grant (“Restricted Stock”), including continued employment and/or achievement of pre-established
performance goals and objectives.

     (b) Acceptance of Award. A participant who is granted a Restricted Stock Award shall have no
rights with respect to such Award unless the participant shall have accepted the Award within ten
(10) days (or such shorter date as the Committee may specify) following the delivery of written
notice to the participant of the Award by making payment to the Company of the specified purchase
price of the shares covered by the Award and by executing and delivering

- 6 -

 

to the Company a written instrument that sets forth the terms and conditions applicable to the
Restricted Stock in such form as the Committee shall determine.

     (c) Rights as a Stockholder. Upon complying with Section 6(b) above, a participant shall have
all the rights of a stockholder with respect to the Restricted Stock, including voting and dividend
rights, subject to non-transferability restrictions and Company repurchase rights described in this
Section 6 and subject to such other conditions contained in the written instrument evidencing the
Restricted Stock Award. Unless the Committee shall otherwise determine, certificates evidencing
shares of Restricted Stock shall remain in the possession of the Company until such shares are
vested as provided in Section 6(e) below.

     (d) Restrictions. Shares of Restricted Stock may not be sold, assigned, transferred, pledged
or otherwise encumbered or disposed of except as specifically provided herein. In the event of
termination of employment with or services to the Company and its Subsidiaries for any reason
(including death, Disability, Normal Retirement, and voluntary termination by the participant), the
Company shall have the right, at the discretion of the Committee, to repurchase shares of
Restricted Stock with respect to which conditions have not lapsed at their purchase price from the
participant or the participant’s legal representative. The Company must exercise such right of
repurchase within sixty (60) days following such termination of employment (unless otherwise
specified in the written instrument evidencing the Restricted Stock Award).

     (e) Vesting of Restricted Stock. The Committee at the time of grant shall specify the date or
dates and/or the attainment of pre-established performance goals, objectives and other conditions
on which the non-transferability of the Restricted Stock and the Company’s right of repurchase
shall lapse. Subsequent to such date or dates and/or the attainment of such pre-established
performance goals, objectives and other conditions, the shares on which all restrictions have
lapsed shall no longer be Restricted Stock and shall be deemed “vested.” Subject to Section 12,
the Committee at any time may accelerate such date or dates and otherwise waive or amend any
conditions of the Award.

     (f) Waiver, Deferral and Reinvestment of Dividends. The written instrument evidencing the
Restricted Stock Award may require or permit the immediate payment, waiver, deferral or investment
of dividends paid on the Restricted Stock.

SECTION 7. Unrestricted Stock Awards

     (a) Grant or Sale of Unrestricted Stock. The Committee in its discretion may grant or sell to
any Eligible Person shares of Stock free of any restrictions under the Plan (“Unrestricted Stock”)
at a purchase price determined by the Committee. Shares of Unrestricted Stock may be granted or
sold as described in the preceding sentence in respect of past services or other valid
consideration.

     (b) Restrictions on Transfers. The right to receive Unrestricted Stock may not be sold,
assigned, transferred, pledged or otherwise encumbered, other than by will or the laws of descent
and distribution.

- 7 -

 

SECTION 8. Performance Share Awards

     A Performance Share Award is an award entitling the recipient to acquire shares of Stock upon
the attainment of specified performance goals. The Committee may make Performance Share Awards
independent of or in connection with the granting of any other Award under the Plan. Performance
Share Awards may be granted under the Plan to any Eligible Person. The Committee in its discretion
shall determine whether and to whom Performance Share Awards shall be made, the performance goals
applicable under each such Award, the periods during which performance is to be measured, the
conditions under which such Award shall terminate, and all other limitations and conditions
applicable to the awarded Performance Shares.

SECTION 9. Termination of Stock Options1

     (a) Standard Termination Provisions. Stock Options shall terminate and no portion
will be exercisable on the earliest to occur of the following:

     (i) Expiration Date. The expiration date of such Stock Option as specified in
the option grant certificate.

     (ii) Termination by Death. If the participant ceases to be an employee of the
Company or its Subsidiaries on account of death, 24 months from the employment termination
date, or 10 days after the end of the blackout period in effect during such post-termination
period, if later, if such participant’s estate or beneficiary is subject to such blackout.

     (iii) Termination by Reason of Disability. If the participant ceases to be an
employee of the Company or a Subsidiary on account of Disability, 12 months from the
employment termination date, or 10 days after the end of the blackout period in effect
during such post-termination period, if later, if such participant is subject to such
blackout.

     (iv) Termination for Cause. If the participant’s employment with the Company
or a Subsidiary is terminated for Cause, the employment termination date.

     (v) Other Termination. If the participant’s employment is terminated in all
other circumstances, 90 days after the employment termination date or 10 days after the end
of the blackout period in effect during such post-termination period, if later, if such
participant is subject to such blackout.

     (b) Post-Termination Exercise Period. During the post-termination exercise period,
the participant may exercise only the portion of Stock Options exercisable on the employment
termination date, and the portion of Stock Options that is not exercisable on the employment
termination date shall be automatically forfeited on the employment termination date. If the
participant’s employment terminates on account of death or Disability, Stock Options shall become
immediately and fully vested and exercisable.

 

			
	1	 	Amended October 2008

- 8 -

 

     (c) Committee Discretion. Notwithstanding the foregoing, the Committee may grant
Stock Options under the Plan which contain such terms and conditions with respect to termination as
the Committee, in its discretion, may from time to time determine.

SECTION 10. Tax Withholding

     (a) Payment by Participant. Each participant shall, no later than the date as of which the
value of an Award or of any Stock or other amounts received thereunder first becomes includable in
the gross income of the participant for Federal income tax purposes, pay to the Company, or make
arrangements satisfactory to the Committee regarding the payment of, any Federal, state, local or
other taxes of any kind required by law to be withheld with respect to such income. The Company
and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes
from any payment of any kind otherwise due to the participant.

     (b) Payment in Shares. A participant may elect, with the consent of the Committee, to have
such tax withholding obligation satisfied, in whole or in part, by (i) authorizing the Company to
withhold from shares of Stock to be issued pursuant to an Award a number of shares with an
aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the
minimum withholding amount due with respect to such Award, or (ii) transferring to the Company
shares of Stock owned by the participant for a period of at least six (6) months and with an
aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the
minimum withholding amount due with respect to such Award.

SECTION 11. Transfer, Leave of Absence, Etc.

     For purposes of the Plan, a transfer to the employment of the Company from a Subsidiary or
from the Company to a Subsidiary, or from one Subsidiary to another, shall not be deemed a
termination of employment. Whether authorized leave of absence, or absence on military or
government service, shall constitute termination of the employment relationship between the Company
and the participant shall be determined by the Committee at the time thereof.

SECTION 12. Amendments and Termination

     The Board may at any time amend or discontinue the Plan in any manner allowed by law and the
Committee may at any time, subject to Section 2, amend or cancel any outstanding Award (or provide
substitute Awards) for the purpose of satisfying changes in law or for any other lawful purpose,
but no such action shall adversely affect rights under any outstanding Award without the holder’s
consent.

SECTION 13. Status of Plan

     With respect to the portion of any Award that has not been exercised, a participant shall have
no rights greater than those of a general creditor of the Company unless the Committee shall
otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the
Committee may authorize the creation of trusts or other arrangements to meet the Company’s
obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the
existence of such trusts or other arrangements is consistent with the provision of the foregoing
sentence.

- 9 -

 

SECTION 14. Lockup Agreement

     The acceptance of any Award under this Plan by the participant or any subsequent holder shall
constitute the agreement of such person that, upon the request of the Company or the underwriters
managing any underwritten offering of the Company’s securities, such person will not, for a period
of time (not to exceed one hundred eighty (180) days) following the effective date of any
registration statement filed by the Company under the Securities Act of 1933, as amended, sell,
make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any
shares of Stock received pursuant to such Award, without the prior written consent of the Company
or such underwriters, as the case may be, and that such person will execute and deliver to the
Company or such underwriters a written agreement to that effect, in such form as the Company or
such underwriters shall designate.

SECTION 15. Change in Control

     (a) Upon the occurrence of a Change of Control as defined in this Section 15:

     (i) subject to the provisions of clause (iii) below, after the effective date of such
Change of Control, each holder of an outstanding Stock Option, Conditional Stock Award,
Performance Share Award or Stock Appreciation Right shall be entitled, upon exercise of such
Award, to receive, in lieu of shares of Stock (or consideration based upon the Fair Market
Value of Stock), shares of such stock or other securities, cash or property (or
consideration based upon shares of such stock or other securities, cash or property) as the
holders of shares of Stock received in connection with the Change of Control;

     (ii) the Committee may accelerate the time for exercise of, and waive all conditions
and restrictions on, each unexercised and unexpired Stock Option, Conditional Stock Award,
Performance Share Award and Stock Appreciation Right, effective upon a date prior or
subsequent to the effective date of such Change of Control, specified by the Committee; or

     (iii) each outstanding Stock Option, Conditional Stock Award, Performance Share Award
and Stock Appreciation Right may be cancelled by the Committee as of the effective date of
any such Change of Control provided that (x) notice of such cancellation shall be given to
each holder of such an Award and (y) each holder of such an Award shall have the right to
exercise such Award to the extent that the same is then exercisable or, if the Committee
shall have accelerated the time for exercise of all such unexercised and unexpired Awards,
in full during the 30-day period preceding the effective date of such Change of Control.

     (b) “Change of Control” shall mean the occurrence of any one of the following events:

     (i) any “person” (as such term is used in Sections 13(d) and 14(d)(2) of the Act)
becomes a “beneficial owner” (as such term is defined in Rule 13d-3 promulgated under the
Act) (other than the Company, any trustee or other fiduciary holding securities under an
employee benefit plan of the Company, or any corporation owned, directly or

- 10 -

 

indirectly, by the shareholders of the Company in substantially the same proportions as
their ownership of stock of the Company), directly or indirectly, of securities of the
Company representing thirty-five percent (35%) or more of the combined voting power of the
Company’s then outstanding securities; or

     (ii) persons who, as of January 1, 1997, constituted the Company’s Board (the
“Incumbent Board”) cease for any reason, including without limitation as a result of a
tender offer, proxy contest, merger or similar transaction, to constitute at least a
majority of the Board, provided that any person becoming a director of the Company
subsequent to January 1, 1997 whose election was approved by, or who was nominated with the
approval of, at least a majority of the directors then comprising the Incumbent Board shall,
for purposes of this Plan, be considered a member of the Incumbent Board; or

     (iii) the shareholders of the Company approve a merger or consolidation of the Company
with any other corporation or other entity, other than (a) a merger or consolidation which
would result in the voting securities of the Company outstanding immediately prior thereto
continuing to represent (either by remaining outstanding or by being converted into voting
securities of the surviving entity) more than 65% of the combined voting power of the voting
securities of the Company or such surviving entity outstanding immediately after such merger
or consolidation or (b) a merger or consolidation effected to implement a recapitalization
of the Company (or similar transaction) in which no “person” (as hereinabove defined)
acquires more than 50% of the combined voting power of the Company’s then outstanding
securities; or

     (iv) the shareholders of the Company approve a plan of complete liquidation of the
Company or an agreement for the sale or disposition by the Company of all or substantially
all of the Company’s assets.

SECTION 16. General Provisions

     (a) No Distribution; Compliance with Legal Requirements. The Committee may require each
person acquiring shares pursuant to an Award to represent to and agree with the Company in writing
that such person is acquiring the shares without a view to distribution thereof, in such form as
the Committee shall in its sole discretion deem advisable.

     No shares of Stock shall be issued pursuant to an Award until, in the opinion of the
Committee, all applicable securities laws and other legal and stock exchange requirements have been
satisfied. The Committee may require the placing of such stop orders and restrictive legends on
certificates for Stock and Awards as it deems appropriate.

     (b) Delivery of Stock Certificates. Delivery of stock certificates to participants under this
Plan shall be deemed effected for all purposes when the Company or a stock transfer agent of the
Company shall have delivered such certificates in the United States mail, addressed to the
participant, at the participant’s last known address on file with the Company.

- 11 -

 

     (c) Other Compensation Arrangements; No Employment Rights. Nothing contained in this Plan
shall prevent the Board from adopting other or additional compensation arrangements, including
trusts, subject to stockholder approval if such approval is required; and such arrangements may be
either generally applicable or applicable only in specific cases. The adoption of the Plan or any
Award under the Plan does not confer upon any employee any right to continued employment with the
Company or any Subsidiary.

SECTION 17. Effective Date of Plan

     The Plan shall become effective upon its adoption by the Board.

SECTION 18. Governing Law

     This Plan and each Award under the Plan shall be governed by, and construed and enforced in
accordance with, the substantive laws of the Commonwealth of Massachusetts without regard to its
principles of conflicts of laws.

- 12 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]